Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | FPR2 | P25090 | 2/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463389 | 0.92 | SMN1; SMN2 (0.57) | SMN1; SMN2GLAKMT2AMTNR1AMTNR1B | |
| SCHEMBL5072982 | 0.91 | POLB (0.58) | SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL9632174 | 0.90 | POLB (0.57) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL25183406 | 0.84 | MTNR1A (0.54) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL6985074 | 0.84 | EPHX2 (0.60) | SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL506516 | 0.84 | HDAC3 (0.60) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL4277213 | 0.84 | POLB (0.48) | SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL2746054 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2GLAKMT2AALDH1A1TAAR1 | |
| SCHEMBL3005286 | 0.83 | MGLL (0.56) | SMN1; SMN2MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL6541474 | 0.83 | POLB (0.50) | SMN1; SMN2KMT2AMTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| EP-4320121-A2 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ULK1/2 INHIBITORS AND THEIR USE THEREOF | LifeArc (GB) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022214869-A2 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
| CN-106459007-B | Pyrimidine-2, 4-diamine derivatives and pharmaceutical compositions for anticancer containing the same as the active ingredient | 韩国化学研究院 | 2020-02-28 | — | — | CN | disclosed |
| US-10100019-B2 | N2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-10-16 | — | — | US | disclosed |
| US-10053458-B2 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-08-21 | — | — | US | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-4971990-A | HYPOTENSIVE AGENTS, DYSUREA | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-20 | — | — | US | disclosed |
| US-4868306-A | Compounds | FISONS PLC (GB) | 1989-09-19 | — | — | US | disclosed |
| EP-0331943-A1 | Phenoxyethylamine derivatives, process for preparing the same, and composition for exhibiting excellent alpha-1-blocking activity containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-09-13 | — | — | EP | disclosed |
| US-4791216-A | Para ethyl amino phenol pharmaceutical compounds | FISONS PLC (GB) | 1988-12-13 | — | — | US | disclosed |
| US-4657929-A | Compounds | FISONS PLC (GB) | 1987-04-14 | — | — | US | disclosed |
| EP-0046666-B1 | 2(3H)-INDOLONES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0142283-A2 | Phenylethylamines, process for their preparation and compositions containing them | FISONS plc (GB) | 1985-05-22 | — | — | EP | disclosed |
| US-4414224-A | 4-AMINO OR SUBSTITUTED AMINO-7-HYDROXY-2-(3H)-INDOLONES | SMITHKLINE BECKMAN CORPORATION (US) | 1983-11-08 | — | — | US | disclosed |
| EP-0046666-A1 | 2(3H)-indolones, process for their preparation and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1982-03-03 | — | — | EP | disclosed |
| US-4314944-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE AGENTS | SMITHKLINE CORPORATION (US) | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | SMN1; SMN2 1653/4885GLA 4214/4885KMT2A 924/4885 |
| US-10053458-B2 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | ALK, NPM1, ETV6 | SMN1; SMN2 2442/4885GLA 4357/4885KMT2A 536/4885 |
| US-10100019-B2 | N2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient | ALK, NPM1, EML4 | SMN1; SMN2 1653/4885GLA 4214/4885KMT2A 924/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | SMN1; SMN2 2564/4885GLA 3355/4885KMT2A 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.